Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Gedye

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 10, 2013
Canadian guideline on genetic screening for hereditary renal cell cancersM Neil Reaume, Gail E Graham, Eva Tomiak, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 10, 2013
Canadian guideline on genetic screening for hereditary renal cell cancersM Neil Reaume, Gail E Graham, Eva Tomiak, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 8